sorafenib has been researched along with Lymphoma, Non-Hodgkin in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y; Gao, J; He, Z; Jia, Y; Tao, H; Wang, F; Wu, P; Zhang, X; Zhou, Z | 1 |
| Chapuy, B; Dohm, A; Hand, E; Panse, M; Schroers, R; Schuelper, N; Truemper, L; Wulf, GG | 1 |
| Adjei, AA; Halling, T; Haug, JL; Kimlinger, TK; Kumar, S; Rajkumar, SV; Ramakrishnan, V; Timm, M; Wellik, LE; Witzig, TE | 1 |
3 other study(ies) available for sorafenib and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
Artesunate synergistically promotes sorafenib‑induced apoptosis and ferroptosis in non‑Hodgkin lymphoma cells through inhibition of the STAT3 pathway.
Topics: Apoptosis; Artesunate; Cell Line, Tumor; Ferroptosis; Humans; Lymphoma, Non-Hodgkin; Sorafenib; STAT3 Transcription Factor | 2023 |
Multikinase inhibitor sorafenib exerts cytocidal efficacy against Non-Hodgkin lymphomas associated with inhibition of MAPK14 and AKT phosphorylation.
Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Cell Cycle; Cell Death; Cell Proliferation; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Humans; Lymphoma, Non-Hodgkin; Mitogen-Activated Protein Kinase 14; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyridines; Signal Transduction; Sorafenib; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2011 |
Sorafenib, a multikinase inhibitor, is effective in vitro against non-Hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Cell Line, Tumor; Drug Screening Assays, Antitumor; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; In Vitro Techniques; Interleukin-6; Lymphoma, Non-Hodgkin; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Pyridines; raf Kinases; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; TOR Serine-Threonine Kinases | 2012 |